335 related articles for article (PubMed ID: 24304248)
21. Environmental pH-sensitive polymeric micelles for cancer diagnosis and targeted therapy.
Gao GH; Li Y; Lee DS
J Control Release; 2013 Aug; 169(3):180-4. PubMed ID: 23195533
[TBL] [Abstract][Full Text] [Related]
22. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
Moura V; Lacerda M; Figueiredo P; Corvo ML; Cruz ME; Soares R; de Lima MC; Simões S; Moreira JN
Breast Cancer Res Treat; 2012 May; 133(1):61-73. PubMed ID: 21805188
[TBL] [Abstract][Full Text] [Related]
23. pH triggered doxorubicin delivery of PEGylated glycolipid conjugate micelles for tumor targeting therapy.
Hu FQ; Zhang YY; You J; Yuan H; Du YZ
Mol Pharm; 2012 Sep; 9(9):2469-78. PubMed ID: 22827551
[TBL] [Abstract][Full Text] [Related]
24. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis.
Huang S; Shao K; Liu Y; Kuang Y; Li J; An S; Guo Y; Ma H; Jiang C
ACS Nano; 2013 Mar; 7(3):2860-71. PubMed ID: 23451830
[TBL] [Abstract][Full Text] [Related]
25. Liposomal cancer therapy: exploiting tumor characteristics.
Kaasgaard T; Andresen TL
Expert Opin Drug Deliv; 2010 Feb; 7(2):225-43. PubMed ID: 20095944
[TBL] [Abstract][Full Text] [Related]
26. Nanotechnology applied to overcome tumor drug resistance.
Gao Z; Zhang L; Sun Y
J Control Release; 2012 Aug; 162(1):45-55. PubMed ID: 22698943
[TBL] [Abstract][Full Text] [Related]
27. Tumor-targeting peptide conjugated pH-responsive micelles as a potential drug carrier for cancer therapy.
Wu XL; Kim JH; Koo H; Bae SM; Shin H; Kim MS; Lee BH; Park RW; Kim IS; Choi K; Kwon IC; Kim K; Lee DS
Bioconjug Chem; 2010 Feb; 21(2):208-13. PubMed ID: 20073455
[TBL] [Abstract][Full Text] [Related]
28. Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment.
Kanapathipillai M; Brock A; Ingber DE
Adv Drug Deliv Rev; 2014 Dec; 79-80():107-18. PubMed ID: 24819216
[TBL] [Abstract][Full Text] [Related]
29. Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy.
She W; Li N; Luo K; Guo C; Wang G; Geng Y; Gu Z
Biomaterials; 2013 Mar; 34(9):2252-64. PubMed ID: 23298778
[TBL] [Abstract][Full Text] [Related]
30. Targeting of nanoparticles in cancer: drug delivery and diagnostics.
Talekar M; Kendall J; Denny W; Garg S
Anticancer Drugs; 2011 Nov; 22(10):949-62. PubMed ID: 21970851
[TBL] [Abstract][Full Text] [Related]
31. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
Danhier F; Feron O; Préat V
J Control Release; 2010 Dec; 148(2):135-46. PubMed ID: 20797419
[TBL] [Abstract][Full Text] [Related]
32. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance.
Fan L; Li F; Zhang H; Wang Y; Cheng C; Li X; Gu CH; Yang Q; Wu H; Zhang S
Biomaterials; 2010 Jul; 31(21):5634-42. PubMed ID: 20430433
[TBL] [Abstract][Full Text] [Related]
33. Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel.
He H; Chen S; Zhou J; Dou Y; Song L; Che L; Zhou X; Chen X; Jia Y; Zhang J; Li S; Li X
Biomaterials; 2013 Jul; 34(21):5344-58. PubMed ID: 23591391
[TBL] [Abstract][Full Text] [Related]
34. pH-sensitive liposomes--principle and application in cancer therapy.
Karanth H; Murthy RS
J Pharm Pharmacol; 2007 Apr; 59(4):469-83. PubMed ID: 17430630
[TBL] [Abstract][Full Text] [Related]
35. Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment.
Chen B; Dai W; He B; Zhang H; Wang X; Wang Y; Zhang Q
Theranostics; 2017; 7(3):538-558. PubMed ID: 28255348
[TBL] [Abstract][Full Text] [Related]
36. Physical mechanisms and methods employed in drug delivery to tumors.
Besić E
Acta Pharm; 2007 Sep; 57(3):249-68. PubMed ID: 17878107
[TBL] [Abstract][Full Text] [Related]
37. Mechanical approaches to oncological drug delivery.
Carlisle R; Coussios CC
Ther Deliv; 2013 Oct; 4(10):1213-5. PubMed ID: 24116903
[No Abstract] [Full Text] [Related]
38. Acid active receptor-specific peptide ligand for in vivo tumor-targeted delivery.
Han L; Guo Y; Ma H; He X; Kuang Y; Zhang N; Lim E; Zhou W; Jiang C
Small; 2013 Nov; 9(21):3647-58. PubMed ID: 23649993
[TBL] [Abstract][Full Text] [Related]
39. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect.
Acharya S; Sahoo SK
Adv Drug Deliv Rev; 2011 Mar; 63(3):170-83. PubMed ID: 20965219
[TBL] [Abstract][Full Text] [Related]
40. pH-sensitive liposomes for drug delivery in cancer treatment.
Ferreira Ddos S; Lopes SC; Franco MS; Oliveira MC
Ther Deliv; 2013 Sep; 4(9):1099-123. PubMed ID: 24024511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
